Table 2.
Sample Demographics Schizophrenia Family Cohorts
| Relatives |
||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Controls |
Cases |
Total |
MZ Co-twins |
DZ Co-twins |
Offspring |
Siblings |
Parents |
|||||||||||||||||||||
| Sample | n | M/F | Age | Other Diagnoses (Y/N) |
n | M/F | Age | Total N |
n | M/F | Age | Other Diagnoses (Y/N) |
n | M/F | Age | Other Diagnoses (Y/N) |
n | M/F | Age | Other Diagnoses (Y/N) |
n | M/F | Age | Other Diagnoses (Y/N) |
n | M/F | Age | Other Diagnoses (Y/N) |
| C_SFS | 23 | 11/12 | 40.2 | 7/16 | 25 | 13/12 | 40.8 | 23 | – | – | – | 13 | 7/6 | 32.5 | 4/9 | 10 | 1/9 | 54.6 | 3/7 | |||||||||
| CliNG-SZa | 20 | 11/9 | 35.7 | 0/20 | – | 20 | – | – | 6 | 3/3 | 26.7 | 0/6 | 7 | 5/2 | 28.4 | 0/7 | 7 | 3/4 | 51.9 | 0/7 | ||||||||
| EHRS | 89 | 44/45 | 21.0 | 0/89 | 31 | 19/12 | 21.8 | 90 | – | – | 57 | 26/31 | 20.9 | 0/57 | 33 | 18/15 | 21.8 | 0/33 | – | |||||||||
| HUBIN | 102 | 69/33 | 41.9 | 29/73 | 103 | 77/26 | 41.2 | 33 | – | – | – | 33 | 23/10 | 39.4 | 8/25 | – | ||||||||||||
| IDIBAPSa | 53 | 21/32 | 12.3 | 12/41 | – | 37 | – | – | 37 | 22/15 | 11.0 | 18/19 | – | – | ||||||||||||||
| IoP-SZ | 67 | 35/32 | 40.9 | 7/60 | 54 | 39/15 | 34.7 | 18 | 14 | 7/7 | 31.0 | 6/8 | 4 | 1/3 | 40.0 | 1/3 | – | – | – | |||||||||
| LIBD | 364 | 163/201 | 32.4 | 3/361 | 215 | 164/51 | 35.3 | 242 | – | – | – | 242 | 100/142 | 36.2 | 83/159 | – | ||||||||||||
| Maastricht- GROUP |
87 | 33/54 | 30.8 | 14/73 | 87 | 59/28 | 28.2 | 95 | – | – | – | 95 | 49/46 | 29.5 | 19/76 | – | ||||||||||||
| MFS-SZa | 54 | 25/29 | 40.2 | 0/54 | 42 | 31/11 | 36.4 | 56 | – | – | – | 20 | 10/10 | 36.4 | 0/20 | 36 | 11/25 | 56.6 | 0/36 | |||||||||
| MooDS-SZa | 65 | 26/39 | 30.6 | 0/65 | – | 63 | – | – | 31 | 10/21 | 26.5 | 0/31 | 25 | 12/13 | 30.2 | 0/25 | 7 | 2/5 | 49.7 | 0/7 | ||||||||
| NU | 92 | 51/41 | 31.9 | 7/85 | 108 | 74/34 | 34.2 | 83 | – | – | – | 83 | 29/54 | 21.1 | 45/38 | – | ||||||||||||
| STAR-SZa | 104 | 49/55 | 48.9 | 22/82 | 49 | 28/21 | 49.5 | 48 | 15 | 9/6 | 41.9 | 0/15 | 33 | 17/16 | 52.3 | 0/33 | – | – | – | |||||||||
| UMCG-GROUP | 37 | 16/21 | 34.0 | 0/37 | – | 45 | – | – | – | 45 | 22/23 | 30.9 | 0/45 | – | ||||||||||||||
| UMCU-DBSOSa | 40 | 21/19 | 12.7 | 7/33 | – | 40 | – | – | 40 | 12/28 | 13.7 | 24/16 | – | – | ||||||||||||||
| UMCU-GROUP | 167 | 83/84 | 27.7 | 13/154 | 162 | 130/32 | 27.0 | 201 | – | – | – | 201 | 95/106 | 27.7 | 52/149 | – | ||||||||||||
| UMCU-Parents | 41 | 14/27 | 52.8 | 0/41 | – | 44 | – | – | – | – | 44 | 13/31 | 52.9 | 11/33 | ||||||||||||||
| UMCU-UTWINSa | 184 | 84/100 | 31.8 | 17/167 | 56 | 33/23 | 35.6 | 45 | 20 | 12/8 | 36.0 | 11/9 | 25 | 17/8 | 37.8 | 5/20 | – | – | – | |||||||||
| UNIBA | 78 | 52/26 | 31.4 | 0/78 | 84 | 58/26 | 33.3 | 45 | – | – | – | 45 | 23/22 | 33.4 | 4/41 | – | ||||||||||||
DZ, dizygotic; F, female; M, male; MZ, monozygotic; N, no; Y, yes.
C_SFS, Calgary Schizophrenia Family Study; CliNG-SZ, Clinical Neuroscience Goettingen - Schizophrenia; EHRS, Edinburgh High Risk Study; HUBIN, Human Brain Informatics; IDIBAPS, August Pi i Sunyer Biomedical Research Institute; IoP-SZ, Institute of Psychiatry - Schizophrenia Twin Study; LIBD, Lieber Institute for Brain Development; Maastricht-GROUP, Maastricht - Genetic Risk and Outcome of Psychosis; MFS-SZ, Maudsley Family Study - Schizophrenia; MooDS-SZ, Systematic Investigation of the Molecular Causes of Major Mood Disorders and Schizophrenia - Schizophrenia; NU, Northwestern University; STAR-SZ, Schizophrenia and Bipolar Twin Study in Sweden - Schizophrenia; UMCG-GROUP, University Medical Center Groningen - Genetic Risk and Outcome of Psychosis; UMCU-DBSOS, University Medical Center Utrecht - Dutch Bipolar and Schizophrenia Offspring Study; UMCU-GROUP, University Medical Center Utrecht - Genetic Risk and Outcome of Psychosis; UMCU-Parents, University Medical Center Utrecht - Parents Study; UMCU-UTWINS, University Medical Center Utrecht - Utrecht Twin Schizophrenia Studies; UNIBA, University of Bari “Aldo Moro.”
Overlapping control subjects with bipolar sample from the same site, i.e., with CliNG-BD (n = 10), IDIBAPS (n = 53), MFS-BD (n = 54), MooDS-BD (n = 36), STAR-BD (n = 100), UMCU-BD twins (n = 27), UMCU-DBSOS (n = 40).